Paul Bessette, M. D.

Investigator Paul Bessette
Cancer : Biology, Prognosis, and Diagnosis Axis
Centre de recherche du CHUS

Obstetrician-Gynecologist-Oncologist
Medical director of Équipe interdisciplinaire supra-régionale de l’Estrie de lutte contre les cancers gynécologiques (ISEL-CCG)
Centre hospitalier universitaire de Sherbrooke

Full Professor
Department of Obstetrics & Gynecology | Gynecologic-Oncology Division
Faculty of Medicine and Health Sciences
Université de Sherbrooke

Contact Information
Phone | 819 346-1110 ext. 13120

E-Mail | Paul.Bessette@USherbrooke.ca

                

Research relevance

As a founding member of the Oncology (cancer) research group of Centre de Recherche du Centre hospitalier universitaire de Sherbrooke, Dr. Paul Bessette is involved in clinical and basic research focusing on gynecologic cancers and its precursors.

                       

To top

Representative Achievements

  • Acting as principal investigator or co-investigator since 1996 in various phase II and III studies in the areas of gynecology-oncology, prevention studies on ovarian and breast cancer, hormone replacement therapy, contraception, anti-emetic therapies, and other studies on women’s health.
  • Founding member of the oncology (cancer) research area at the Centre de Recherche Clinique du CUSE/CHUS/Étienne-Le Bel du CHUS since 1997
  • Member of the National Cancer Institute of Canada clinical trials group NCIC CTG (gynecologic disease site committee) and the Canadian Cancer Society research institute
  • Member of the INHERIT BRCAs “Interdisciplinary Health Research International Team on Breast Cancer Susceptibility” research group
  • Co-investigator of a Randomized Trial of Concurrent Chemoradiation for High Risk and Advanced Stage Endometrial Carcinoma PORTEC – 3 / NCIC EN7
  • Valeur de la cytologie gynécologique et du taux de CA 125 pour la prévision de la maladie extra-utérine dans les cas de cancer de l'endomètre.] Brassard L, Bessette P. J ObstetGynaecol Can. 2012 Jul;34(7):657-663.
  • Resident Research Training Objectives and Requirements of the Association of Academic Professionals in Obstetrics and Gynaecology. Smith GN, McNamara H, Bessette P, Allen VM, Ross S, Schulz J, Pierson R, Nadeau B; APOG Research Committee. J ObstetGynaecol Can. 2011 Oct;33(10):1044-6.
  • A Phase 3 Trial of Bevacizumab in Ovarian Cancer. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators (including Bessette P). N Engl J Med. 2011 Dec 29;365(26):2484-96.
  • Endometrioid Ovarian Cancer and Endometriotic Cells Exhibit the Same Alteration in the Expression of Interleukin-1 Receptor II: To a Link between Endometriosis and Endometrioid Ovarian Cancer. Keita M, AinMelk Y, Pelmus M, Bessette P, Aris A. J ObstetGynaecolRes. 2011 Feb;37(2):99-107

                        

Know-How & Opportunities for Collaboration

  • Oncology and advanced gynecologic surgery
  • Systemic therapy of cancer (chemotherapy and biologic response modifying agents)
  • Symptoms control and genetic of gynecologic cancers

                                  

To top